

Veterinary Dermatology Market by Route of Administration, Product type (Antibacterial, Antifungal, Antiparasitic Drugs, Monoclonal Antibodies), Condition type (Parasitic Infections, Infectious Diseases, Skin Cancer), Animal type - Global Forecast to 2030

Market Report | 2025-02-27 | 385 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global veterinary dermatology market is projected to reach USD 30.31 billion by 2030 from USD 20.11 billion in 2025, at a CAGR of 8.5% during the forecast period. The Veterinary Dermatology Market is experiencing significant growth, driven by the expanding companion animal population and increasing pet ownership. Growing concerns about infectious zoonotic diseases have further influenced the demand for dermatological treatments. Government and animal welfare organizations are actively promoting awareness initiatives, encouraging early diagnosis and treatment of dermatological conditions in both pets and farm animals. Moreover, the rising adoption of pet insurance and high animal healthcare expenditure are supporting market growth by improving access to specialized dermatological care. However, the market faces challenges such as the rising cost of pet care, which can limit treatment adoption. Additionally, increasing resistance to parasiticides poses a significant concern, reducing the effectiveness of common dermatological treatments. Despite these restraints, advancements in veterinary dermatology, including novel therapeutics and diagnostic techniques, continue to drive market opportunities.

"The Oral segment is projected to grow at the highest CAGR during the forecast period of 2025-2030." The oral segment is projected to grow at the highest CAGR during 2025-2030 due to its ease of administration and improved pet owner compliance. Oral medications, including tablets, capsules, and chewable formulations, offer a convenient alternative to topical and injectable treatments. Increasing veterinary recommendations for systemic treatments over topical solutions and the development of palatable formulations are boosting demand. Additionally, advancements in drug delivery systems, such as sustained-release oral formulations, contribute to the segment's growth in the veterinary dermatology market.

"Antiparasitic Drugs segment accounted the largest market in 2024 in veterinary dermatology market." The antiparasitic drugs segment accounted for the largest market share in 2024 due to the rising prevalence of parasitic infections in animals. These drugs, including flea and tick preventives, are widely used for both treatment and prevention. Increasing pet adoption and awareness about zoonotic diseases are fueling the demand for antiparasitic treatments. Moreover, the growing availability of combination therapies that target multiple parasites has driven market expansion. Key industry players are launching innovative formulations with improved efficacy and longer protection durations, further strengthening the segment's dominance.

" Parasitic infection is expected to witness the fastest growth rate in the global veterinary dermatology market." Parasitic infections are expected to witness the fastest growth rate in the veterinary dermatology market. The high incidence of flea, tick, and mite infestations in pets, especially in warm and humid regions, is driving demand for effective treatments. Parasitic dermatitis can cause severe itching, hair loss, and secondary bacterial infections, increasing the need for veterinary care. Advancements in diagnostic methods and increasing availability of prescription and over-the-counter treatments contribute to the segment's rapid growth. Moreover, heightened pet owner awareness of parasite prevention further supports market expansion.

"Companion animals segment has accounted the largest market share in the veterinary dermatology market." The companion animals segment accounted for the largest market share in 2024, driven by increasing pet ownership and growing expenditure on animal healthcare. Dogs and cats are highly susceptible to skin conditions such as allergies, fungal infections, and ectoparasitic infestations, necessitating frequent dermatological treatments. The rising trend of pet humanization and demand for premium veterinary care further boost market growth. Additionally, advancements in dermatological therapeutics, including biologics and targeted therapies, enhance treatment outcomes for companion animals, reinforcing the segment's dominance in the market.

"Veterinary Hospitals and Clinics segment is expected to witness the highest growth rate in the global veterinary dermatology market."

Veterinary hospitals and clinics are expected to witness the highest growth rate, driven by the increasing number of veterinary visits and the availability of specialized dermatology services. These facilities provide comprehensive treatment options, including advanced diagnostics, prescription medications, and surgical interventions for severe skin conditions. The rise in dermatology-focused veterinary clinics and expansion of telemedicine services for dermatological consultations contribute to segment growth. Additionally, pet insurance coverage for dermatological treatments encourages pet owners to seek veterinary care, further increasing demand in this segment.

"North America has accounted for the largest market share in 2024."

North America accounted for the largest market share in 2024, supported by a well-established veterinary healthcare infrastructure and high pet ownership rates. The region has a strong presence of leading market players investing in research and development for innovative dermatological treatments. Rising awareness about pet skin health, coupled with increasing spending on veterinary care, drives market expansion. Additionally, the growing demand for premium pet dermatology products, including hypoallergenic shampoos, medicated sprays, and prescription drugs, contributes to North America's market dominance in the global veterinary dermatology industry.

Breakdown of supply-side primary interviews: - By Company Type: Tier 1 - 45%, Tier 2 - 20%, and Tier 3 - 35% - By Designation: C-level - 35%, Director-level - 25%, and Others - 40% - By Region: North America - 40%, Europe - 25%, APAC - 20%, Latin America - 10%, Middle East & Africa - 5%

Breakdown of demand-side primary interviews: - By Company Type: Vterinary Hospitals and Clinics - 55%, Animal Shelters and

Clinics - 30%, and Other End Users - 15% - By Designation: Veterinary Professionals - 35%, Pet Owners - 30%, Livestock Farmers - 25% and Governtment Officers - 10% - By Region: North America - 40%, Europe - 25%, APAC - 20%, Latin America - 10%, Middle East & Africa - 5%

Research Coverage

This report studies veterinary dermatology market based on route of administration, product types, condition types, animal types, end users, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

-[Analysis of key drivers (Expanding companion animal population and pet ownership, Growing concerns about infectious zoonotic diseases, Rising Awareness initiatives by government and animal welfare organizations, Increasing adoption of pet insurance and high animal healthcare expenditure), restraints (Rising pet care costs, Restrictions on use of parasiticides for food-producing animals), opportunities (Technological advancements and product launches, High growth potential in emerging economies, Surging number of veterinary practitioners in developed markets), and challenges (Growing resistance to parasiticides, Diversity in parasite species) influencing the growth of veterinary dermatology market.

- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in veterinary dermatology market.

- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of veterinary dermatology treatments across regions.

- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in veterinary dermatology market.

- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in veterinary dermatology market.

Table of Contents:

1[INTRODUCTION[]32 1.1[]STUDY OBJECTIVES[]32 1.2[]MARKET DEFINITION[]33 1.2.1[INCLUSIONS AND EXCLUSIONS[]33 1.3[]STUDY SCOPE[]34 1.3.1[]YEARS CONSIDERED[]35 1.4[]CURRENCY CONSIDERED[]35 1.4[]CURRENCY CONSIDERED[]35 1.5[]STAKEHOLDERS[]36 2[]RESEARCH METHODOLOGY[]37 2.1[]RESEARCH APPROACH[]37 2.1.1[]SECONDARY DATA[]38 2.1.1.1[]Key data from secondary sources[]40 2.1.2[]PRIMARY DATA[]40 2.1.2.1[]Key industry insights[]43

2.2 MARKET SIZE ESTIMATION 45 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 51 2.4 MARKET SHARE ESTIMATION 51 2.5 RESEARCH ASSUMPTIONS 52 2.6 RISK ASSESSMENT 52 2.7 RESEARCH LIMITATIONS 53 2.7.1 METHODOLOGY-RELATED LIMITATIONS 53 2.7.2 SCOPE-RELATED LIMITATIONS 53 3 EXECUTIVE SUMMARY 54 4 PREMIUM INSIGHTS 60 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN VETERINARY DERMATOLOGY MARKET 60 4.2 NORTH AMERICA: VETERINARY DERMATOLOGY MARKET OVERVIEW 61 4.3 VETERINARY DERMATOLOGY MARKET: REGIONAL MIX 62 4.4 VETERINARY DERMATOLOGY MARKET, BY COUNTRY 62 4.5 VETERINARY DERMATOLOGY MARKET: EMERGING VS. DEVELOPED MARKETS 63 ? 5 MARKET OVERVIEW 64 5.1 INTRODUCTION 64 5.2 MARKET DYNAMICS 65 5.2.1 || DRIVERS || 65 5.2.1.1 Expanding companion animal population and pet ownership 65 5.2.1.2 Growing concerns about infectious zoonotic diseases 68 5.2.1.3 Rising awareness initiatives by government and animal welfare organizations 70 5.2.1.4 Increasing adoption of pet insurance and high animal healthcare expenditure 70 5.2.2 RESTRAINTS 72 5.2.2.1 Rising pet care costs 72 5.2.2.2 Restrictions on use of parasiticides for food-producing animals 72 5.2.3 OPPORTUNITIES 73 5.2.3.1 Technological advancements and product launches 73 5.2.3.2 High growth potential in emerging economies 73 5.2.3.3 Surging number of veterinary practitioners in developed markets 74 5.2.4 CHALLENGES 75 5.2.4.1 Growing resistance to parasiticides 75 5.2.4.2 Diversity in parasite species 76 5.3 INDUSTRY TRENDS 76 5.3.1 RISE IN PET OWNERSHIP, HUMANIZATION OF PETS, AND INCREASED FOCUS ON PET WELLNESS PROGRAMS 76 5.3.2 RISING USE OF DIAGNOSTICS AND WEARABLE TECHNOLOGY FOR EARLY DETECTION 76 5.4 TECHNOLOGY ANALYSIS 77 5.4.1 KEY TECHNOLOGIES 77 5.4.1.1 || Topical nanomedicine || 77 5.4.1.2 Biologic therapies 77 5.4.2 COMPLEMENTARY TECHNOLOGIES 78 5.4.2.1 Phototherapy 78 5.4.2.2 Hydrotherapy 78 5.4.3 ADJACENT TECHNOLOGIES 78 5.4.3.1 Telemedicine platforms 79 5.4.3.2 Wearable devices 79

5.5 PORTER'S FIVE FORCES ANALYSIS 79 5.5.1 COMPETITIVE RIVALRY 80 5.5.1.1 Established players 80 5.5.1.2 Continuous innovation 80 5.5.2 BARGAINING POWER OF BUYERS 80 5.5.2.1 Consolidated veterinary groups 80 5.5.2.2 Demand for affordable solutions 80 ? 5.5.3 BARGAINING POWER OF SUPPLIERS 80 5.5.3.1 Specialized raw materials 80 5.5.3.2 Quality compliance 80 5.5.4 THREAT OF SUBSTITUTES 81 5.5.4.1 Limited alternatives 81 5.5.4.2 Specialized treatments 81 5.5.5 THREAT OF NEW ENTRANTS 81 5.5.5.1 High R&D costs 81 5.5.5.2 Regulatory requirements 81 5.6 REGULATORY LANDSCAPE 82 5.6.1 REGULATORY ANALYSIS 82 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 5.7 PATENT ANALYSIS 87 5.7.1 PATENT PUBLICATION TRENDS FOR VETERINARY DERMATOLOGY MARKET 87 5.7.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 88 5.8 TRADE ANALYSIS 91 5.8.1 IMPORT AND EXPORT SCENARIO FOR VETERINARY DERMATOLOGY PRODUCTS 91 5.9 PRICING ANALYSIS 92 5.9.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT TYPE 92 5.9.2 AVERAGE SELLING PRICE TREND OF VETERINARY DERMATOLOGY PRODUCT TYPES, BY REGION 93 5.10 REIMBURSEMENT ANALYSIS 95 5.11 KEY CONFERENCES AND EVENTS 96 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 5.12.1 || KEY STAKEHOLDERS IN BUYING PROCESS || 97 5.12.2 BUYING CRITERIA 97 5.13 UNMET NEEDS/END USER EXPECTATIONS IN VETERINARY DERMATOLOGY MARKET 98 5.14 IMPACT OF GENERATIVE AI ON VETERINARY DERMATOLOGY MARKET 99 5.15 ECOSYSTEM ANALYSIS 99 5.16 CASE STUDY ANALYSIS 101 5.16.1 ZOETIS LAUNCHED APOQUEL TABLET FOR ALLERGIC DERMATITIS 101 5.16.2 ELANCO LAUNCHED ZENRELIA TABLET FOR CANINE ATOPIC DERMATITIS 5.16.3 VIRBAC LAUNCHED ALLERDERM SPOT-ON TOPICAL PRODUCT FOR SKIN BARRIER REPAIR 5.17 SUPPLY CHAIN ANALYSIS 103 5.18 VALUE CHAIN ANALYSIS 104 5.19 ADJACENT MARKETS FOR VETERINARY DERMATOLOGY MARKET 105 5.20 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 106 5.21 INVESTMENT AND FUNDING SCENARIO 107 ?

6 VETERINARY DERMATOLOGY MARKET, BY ROUTE OF ADMINISTRATION 108

6.1 INTRODUCTION 109 6.2 TOPICAL 109 6.2.1 HIGH PREVALENCE OF ECTOPARASITIC INFESTATIONS AMONG PETS TO DRIVE DEMAND 109 6.3 INJECTABLES 113 6.3.1 RAPID ABSORPTION AND HIGH BIOAVAILABILITY TO FUEL GROWTH OF INJECTABLE PRODUCTS 6.4⊓ORAL⊓115 6.4.1 COMPREHENSIVE APPROACH TO MANAGING CHRONIC AND SEVERE DERMATOLOGICAL DISORDERS 7 VETERINARY DERMATOLOGY MARKET, BY PRODUCT TYPE 117 7.1 INTRODUCTION 118 7.2 ANTIPARASITIC DRUGS 118 7.2.1 HIGH PREVALENCE OF PARASITIC INFECTIONS IN ANIMALS TO DRIVE DEMAND 7.3 ANTIFUNGAL DRUGS 122 7.3.1 INCREASING INSTANCES OF YEAST DERMATITIS AND CANDIDIASIS TO DRIVE DEMAND 7.4 ANTIBACTERIAL DRUGS 125 7.4.1 GROWTH HINDERED BY RISING CONCERNS OVER ANTIMICROBIAL RESISTANCE 125 7.5 MONOCLONAL ANTIBODIES 127 7.5.1 RISING INVESTMENT IN R&D TO BOOST SEGMENTAL GROWTH 127 7.6 OTHER PRODUCT TYPES 129 8 VETERINARY DERMATOLOGY MARKET, BY CONDITION TYPE 131 8.1⊓INTRODUCTION⊓132 8.2 PARASITIC INFECTIONS 132 8.2.1 HIGH OCCURRENCE IN BOTH COMPANION AND LIVESTOCK ANIMALS TO DRIVE DEMAND FOR PREVENTIVE MEASURES 132 8.3 INFECTIOUS DISEASES 134 8.3.1 HIGH PREVALENCE OF FUNGAL INFECTIONS TO DRIVE GROWTH 134 8.4 AUTOIMMUNE SKIN DISEASES 136 8.4.1 LOWER OCCURRENCE OF THESE DISEASES CONTRIBUTE TO SMALLER MARKET SHARE 136 8.5 SKIN CANCER 138 8.5.1 □ GROWING AWARENESS ABOUT IMPORTANCE OF EARLY DETECTION AND TREATMENT OF SKIN CANCER TO DRIVE GROWTH[]138 8.6 OTHER CONDITION TYPES 140 ? 9 VETERINARY DERMATOLOGY MARKET, BY ANIMAL TYPE 142 9.1 INTRODUCTION 143 9.2 COMPANION ANIMALS 143 9.2.1 DOGS 146 9.2.1.1 Growing dog population and high pet ownership to drive growth 146 9.2.2 CATS 148 9.2.2.1 Growing awareness of feline health to drive growth 148 9.2.3 HORSES 150 9.2.3.1 Initiatives related to adoption to drive growth 150 9.2.4 OTHER COMPANION ANIMALS 152 9.3 LIVESTOCK ANIMALS 154 9.3.1 CATTLE 156 9.3.1.1 Economic importance of dairy and beef cattle to drive growth 156 9.3.2 SWINE 158 9.3.2.1 Rising global swine population and pork consumption to drive growth 158 9.3.3 POULTRY 160

9.3.3.1 Increasing demand for milk and dairy products to drive growth 160 9.3.4 OTHER LIVESTOCK ANIMALS 162 10 VETERINARY DERMATOLOGY MARKET, BY END USER 164 10.1 INTRODUCTION 165 10.2 VETERINARY HOSPITALS AND CLINICS 165 10.2.1 GROWING DEMAND FOR SPECIALIZED SKINCARE AND TREATMENTS TO DRIVE MARKET 165 10.3 ANIMAL SHELTERS AND RESCUES 167 10.3.1 NGO AND ANIMAL WELFARE ORGANIZATIONS TO KEEP SUPPORTING DERMATOLOGICAL TREATMENT IN VETERINARY MARKET 167 10.4 OTHER END USERS 169 11 VETERINARY DERMATOLOGY MARKET, BY REGION 171 11.1 INTRODUCTION 172 11.2 NORTH AMERICA 173 11.2.1 MACROECONOMIC OUTLOOK 173 11.2.2 US 179 11.2.2.1 High pet ownership rates to drive growth 179 11.2.3 CANADA 183 11.2.3.1 Rising concerns about pet skin health to drive market 183 11.3[]EUROPE[]187 11.3.1 MACROECONOMIC OUTLOOK 187 11.3.2 GERMANY 192 11.3.2.1 Rising poultry consumption and dairy industry to drive market 192 ? 11.3.3 UK 196 11.3.3.1 Large pet ownership and zoonotic disease prevention to drive market 196 11.3.4 FRANCE 200 11.3.4.1 Stable animal healthcare spending to support market growth 200 11.3.5 || ITALY || 203 11.3.5.1 Expanding livestock industry to drive market 203 11.3.6 SWITZERLAND 206 11.3.6.1 High standards in animal health to drive growth 206 11.3.7 SPAIN 210 11.3.7.1 Growing pet population and strong dairy industry to drive market 210 11.3.8 REST OF EUROPE 213 11.4 ASIA PACIFIC 217 11.4.1 MACROECONOMIC OUTLOOK 217 11.4.2 JAPAN 223 11.4.2.1 [Rising demand for animal products and increasing pet ownership to drive growth]223 11.4.3 CHINA 227 11.4.3.1 Expanding urban pet market and high meat consumption to fuel market 227 11.4.4 [INDIA] 231 11.4.4.1 Growing pet adoption and veterinary shortage to drive market 231 11.4.5 AUSTRALIA 235 11.4.5.1 Growing pet ownership and rising spending on veterinary care to drive market 235 11.4.6 NEW ZEALAND 238 11.4.6.1 Increased pet ownership and demand for advanced dermatology treatments to drive market 238 11.4.7 SOUTH KOREA 242

11.4.7.1 Increasing awareness and adoption of preventive healthcare measures to drive market 242 11.4.8 REST OF ASIA PACIFIC 245 11.5 LATIN AMERICA 249 11.5.1 MACROECONOMIC OUTLOOK 249 11.5.2[]BRAZIL[]254 11.5.2.1 Strong veterinary infrastructure and expanding livestock industry to drive market 254 11.5.3 MEXICO 258 11.5.3.1 Expanding livestock and poultry sectors to drive market 258 11.5.4 REST OF LATIN AMERICA 261 11.6 MIDDLE EAST & AFRICA 264 11.6.1 MACROECONOMIC OUTLOOK 264 11.6.2 GCC COUNTRIES 268 11.6.2.1 Kingdom of Saudi Arabia (KSA) 271 11.6.2.1.1 Vision 2030 investments to drive market 271 11.6.2.2 United Arab Emirates (UAE) 274 11.6.2.2.1 Significant livestock population to fuel demand 274 11.6.2.3 Rest of GCC Countries 277 11.6.3 REST OF MIDDLE EAST & AFRICA 280 12 COMPETITIVE LANDSCAPE 284 12.1 OVERVIEW 284 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN 284 12.3 REVENUE ANALYSIS OF KEY PLAYERS IN VETERINARY DERMATOLOGY MARKET (2020?2024) 285 12.4 MARKET SHARE ANALYSIS, 2024 286 12.4.1 RANKING OF KEY MARKET PLAYERS, 2024 289 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 289 12.5.1 STARS 289 12.5.2 EMERGING LEADERS 289 12.5.3 PERVASIVE PLAYERS 289 12.5.4 PARTICIPANTS 290 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 291 12.5.5.1 Company footprint 291 12.5.5.2 Region footprint 292 12.5.5.3 Route of administration footprint 293 12.5.5.4 Product type footprint 294 12.5.5.5 Condition type footprint 295 12.5.5.6 Animal type footprint 296 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 297 12.6.1 PROGRESSIVE COMPANIES 297 12.6.2 RESPONSIVE COMPANIES 297 12.6.3 DYNAMIC COMPANIES 297 12.6.4 STARTING BLOCKS 297 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 299 12.7 BRAND/PRODUCT COMPARISON 301 12.8 R&D EXPENDITURE OF KEY PLAYERS 302 12.9 COMPANY VALUATION AND FINANCIAL METRICS 302 12.9.1 COMPANY VALUATION 302 12.9.2 FINANCIAL METRICS 303

12.10 COMPETITIVE SCENARIO 303 12.10.1 PRODUCT APPROVALS/LAUNCHES 303 12.10.2 DEALS 304 12.10.3 EXPANSIONS 305 12.10.4 OTHER DEVELOPMENTS 306 ? 13 COMPANY PROFILES 307 13.1 KEY PLAYERS 307 13.1.1 ELANCO ANIMAL HEALTH INCORPORATED 307 13.1.1.1 Business overview 307 13.1.1.2 Products offered 308 13.1.1.3 Recent developments 310 13.1.1.3.1 Product launches and approvals 310 13.1.1.3.2 Deals 310 13.1.1.3.3 Expansions 311 13.1.1.4 MnM view 311 13.1.1.4.1 Right to win 311 13.1.1.4.2 Strategic choices 311 13.1.1.4.3 Weaknesses and competitive threats 312 13.1.2 MERCK & CO., INC 313 13.1.2.1 Business overview 313 13.1.2.2 Products offered 314 13.1.2.3 Recent developments 315 13.1.2.3.1 Product launches and approvals 315 13.1.2.3.2[]Deals[]316 13.1.2.3.3 Expansions 317 13.1.2.3.4 Other developments 317 13.1.2.4 MnM view 317 13.1.2.4.1 Right to win 317 13.1.2.4.2 Strategic choices 318 13.1.2.4.3 Weaknesses and competitive threats 318 13.1.3 VIRBAC 319 13.1.3.1 Business overview 319 13.1.3.2 Products offered 320 13.1.3.3 Recent developments 321 13.1.3.3.1 Deals 321 13.1.3.3.2 Expansions 322 13.1.3.3.3 Other developments 322 13.1.3.4 MnM view 322 13.1.3.4.1 Right to win 322 13.1.3.4.2 Strategic choices 323 13.1.3.4.3 Weaknesses and competitive threats 323 ? 13.1.4 ZOETIS INC. 324 13.1.4.1 Business overview 324 13.1.4.2 Products offered 325 13.1.4.3 Recent developments 326

13.1.4.3.1 Product launches and approvals 326 13.1.4.3.2 Deals 327 13.1.4.3.3 Expansions 327 13.1.4.3.4 Other developments 328 13.1.4.4 MnM view 328 13.1.4.4.1 Right to win 328 13.1.4.4.2 Strategic choices 328 13.1.4.4.3 Weaknesses and competitive threats 329 13.1.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 330 13.1.5.1 Business overview 330 13.1.5.2 Products offered 331 13.1.5.3 Recent developments 332 13.1.5.3.1 Product approvals 332 13.1.5.3.2 Deals 332 13.1.5.4 MnM view 332 13.1.5.4.1 Right to win 332 13.1.5.4.2 Strategic choices 333 13.1.5.4.3 Weaknesses and competitive threats 333 13.1.6 VETOQUINOL 334 13.1.6.1 Business overview 334 13.1.6.2 Products offered 335 13.1.6.3 Recent developments 336 13.1.6.3.1 Product approvals 336 13.1.7 DECHRA PHARMACEUTICALS PLC 337 13.1.7.1 Business overview 337 13.1.7.2 Products offered 338 13.1.7.3 Recent developments 339 13.1.7.3.1 Product approvals 339 13.1.7.3.2 Deals 340 13.1.8 HESTER BIOSCIENCES LIMITED 341 13.1.8.1 Business overview 341 13.1.8.2 Products offered 343 13.1.9 PETIQ, INC. 344 13.1.9.1 Business overview 344 13.1.9.2 Products offered 345 13.1.9.3 Recent developments 346 13.1.9.3.1 Other developments 346 ? 13.1.10 OUROFINO SAUDE ANIMAL 347 13.1.10.1 Business overview 347 13.1.10.2 Products offered 348 13.1.11 SWEDENCARE 349 13.1.11.1 Business overview 349 13.1.11.2 Products offered 350 13.1.11.3 Recent developments 351 13.1.11.3.1 Deals 351 13.1.12 ORION CORPORATION 353

13.1.12.1 Business overview 353 13.1.12.2 Products offered 354 13.1.13 NORBROOK 355 13.1.13.1 Business overview 355 13.1.13.2 Products offered 356 13.1.13.3 Recent developments 357 13.1.13.3.1 Product launches 357 13.1.13.3.2 Expansions 358 13.1.14 CEVA SANTE ANIMALE 359 13.1.14.1 Business overview 359 13.1.14.2 Products offered 359 13.1.14.3 Recent developments 360 13.1.14.3.1 Deals 360 13.1.15 BIMEDA, INC. 361 13.1.15.1 Business overview 361 13.1.15.2 Products offered 361 13.1.15.3 Recent developments 362 13.1.15.3.1 Product launches 362 13.1.15.3.2 Deals 362 13.2 OTHER PLAYERS 363 13.2.1 INDIAN IMMUNOLOGICALS LTD. 363 13.2.2 VETANCO 364 13.2.3 CHANELLE PHARMA 365 13.2.4 PEGASUS LABORATORIES, INC. 366 13.2.5 KYORITSU SEIYAKU CORPORATION 367 13.2.6 AVET HEALTH 368 13.2.7 ANIMALDERMA SRLS 369 13.2.8 LETI PHARMA 370 13.2.9 HUVEPHARMA, INC. 371 13.2.10 VETPLUS 372 ? 14 APPENDIX 373 14.1 DISCUSSION GUIDE 373 14.2[KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL]381 14.3 CUSTOMIZATION OPTIONS 383 14.4 RELATED REPORTS 383 14.5 AUTHOR DETAILS 384



Veterinary Dermatology Market by Route of Administration, Product type (Antibacterial, Antifungal, Antiparasitic Drugs, Monoclonal Antibodies), Condition type (Parasitic Infections, Infectious Diseases, Skin Cancer), Animal type - Global Forecast to 2030

Market Report | 2025-02-27 | 385 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License		Price
	Single User		\$4950.00
	Multi User		\$6650.00
	Corporate License		\$8150.00
	Enterprise Site License		\$10000.00
		VAT	
		Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. []** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	Phone*	
First Name*	Last Name*	
Job title*		
Company Name*	EU Vat / Tax ID / NIF	P number*
Address*	City*	

7in	Code*
Zip	Code

Country*

Date

Signature

2025-05-20